Cartilage repair

Cartilage repair is a physiological and therapeutic process rather than a single molecular target or receptor. It refers to the restoration of articular cartilage, which possesses a limited intrinsic capacity for self-repair due to its avascular nature and low mitotic activity of resident chondrocytes [1][4]. The process involves a coordinated cascade of chondrocyte proliferation, differentiation of mesenchymal stem cells, and the synthesis of a specialized extracellular matrix (ECM) rich in type II collagen and proteoglycans. In pathological states like osteoarthritis, the balance shifts toward catabolism, where enzymes such as matrix metalloproteinases (MMPs) and ADAMTS degrade the tissue faster than it can be replaced [2]. Therapeutic approaches to cartilage repair target specific signaling pathways to favor anabolism. For instance, Sprifermin (recombinant human FGF18) targets fibroblast growth factor receptor 3 (FGFR3) to induce chondrocyte hypertrophy and matrix production, while Lorecivivint modulates the Wnt pathway to prevent cartilage breakdown [3][5]. Because 'Cartilage repair' describes a clinical outcome or biological process involving multiple proteins and cell types, it is classified as an incorrect entry for a specific molecular target. Analysts should instead focus on specific pathway components like FGFR3, Wnt/beta-catenin, or TGF-beta receptors when evaluating molecular interventions [4][5].

Other names

ChondrogenesisArticular cartilage restorationCartilage regenerationChondral repair

Pharmacological interventions aim to stimulate chondrocyte proliferation via FGFR3 signaling (e.g., Sprifermin), inhibit catabolic Wnt signaling (e.g., Lorecivivint), or provide viscoelastic supplementation to the extracellular matrix (e.g., Hyaluronic acid) [1][2].